查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1663468

生物製剂合约开发市场，按服务类型、生物製剂类型、最终用户、国家和地区划分 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Biologics Contract Development Market, By Service Type, By Biologics Type, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年生物製剂合约开发市场规模价值为 75.0965 亿美元，2025 年至 2032 年的复合年增长率为 8.94%。

生物製剂合约开发市场-市场动态

个人化医疗需求的不断增长推动了生物製剂合约开发的成长。

个人化医疗的需求不断成长，是生物製剂合约开发市场的重要推手。个人化医疗根据个人基因特征客製化治疗方案，提高疗效并减少副作用。根据美国国立卫生研究院（NIH）的数据，到2025年全球个人化医疗市场规模预计将达到3.5兆美元。

由于生物疗法对于个人化医疗至关重要，因此对专业合约开发服务的需求日益增长。遗传疾病和癌症的发生率不断上升，进一步刺激了对生物製剂的需求，美国国立卫生研究院估计，全球约有十分之一的人患有罕见疾病，其中许多人需要生物治疗。这些因素促使生物製药公司与合约开发组织合作，以获得必要的专业知识并有效扩大生产规模。

生物製剂合约开发市场 - 关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年），全球市场预计年复合成长率约为 8.94%

根据服务类型细分，预计合约製造将在 2024 年占据最大市场份额

根据生物製剂类型细分，单株抗体是 2024 年领先的生物製剂类型

从地区来看，北美是 2024 年的主要收入来源

生物製剂合约开发市场-細項分析：

全球生物製剂合约开发市场根据服务类型、生物製剂类型、最终用户和地区进行细分。

根据服务类型，市场分为三类：合约研究、合约製造和合约测试。生物製剂合约开发市场中最主要的部分是合约製造。由于对单株抗体和疫苗等生物药物大规模生产的需求不断增加，该领域实现了大幅成长。合约製造组织 (CMO) 为生物製药公司提供高效生产生物製剂同时保持法规合规性所需的专业知识、设施和设备。由于生物疗法需要细胞培养和发酵等专门的过程，因此外包这些服务有助于公司降低成本并缩短上市时间。对可扩展製造解决方案的需求，特别是随着个人化医疗和复杂疾病生物疗法的兴起，巩固了这一领域的重要性。

根据生物製剂类型，市场分为四大类：单株抗体、疫苗、基因疗法和重组蛋白。生物製剂合约开发市场中最主要的部分是单株抗体。这个细分市场处于领先地位，因为在治疗癌症、自体免疫疾病和传染病等各种疾病方面，对单株抗体 (mAb) 的需求不断增长。 mAb 具有高度特异性，可提供针对性治疗，与传统药物相比，具有更好的疗效和更少的副作用。随着生物技术的进步，许多新的 mAb 已被开发出来，并被广泛应用于个人化医疗。因此，合约开发组织（CDO）越来越专注于提供 mAb 开发和製造服务，使得这一领域成为生物製剂合约开发市场中最突出的领域。

生物製剂合约开发市场-地理洞察

北美占据生物製剂合约开发市场的很大份额，这得益于其强大的医疗保健基础设施、强大的研究能力以及对生物疗法的高需求。美国食品药物管理局（FDA）在监管生物製剂、确保治疗安全性和有效性方面发挥关键作用，增强了市场信心。北美拥有多家领先的生物製药公司、学术机构和合约开发组织，是生物製剂开发的重要枢纽。美国癌症、自体免疫疾病等慢性病发生率较高，进一步加速了对生物治疗的需求。此外，该地区的医疗保健政策支持个人化医疗的创新和报销，吸引了对生物製剂的大量投资。将製造和开发服务外包给专业 CDO 的趋势日益增长，也促进了市场的成长。随着基因组学和生物技术的进步，北美将继续在生物製剂开发和合约服务领域保持领先地位。

美国在生物製剂合约开发市场中占据主导地位，得益于其先进的医疗保健体系、领先的製药公司和尖端的研究机构。美国食品药物管理局（FDA）提供了一个完善的监管框架，确保生物製品的安全性和有效性，并增强了市场信心。该国癌症、糖尿病和自体免疫疾病等慢性病发病率很高，这推动了对生物治疗的需求。此外，美国在生物技术和製药创新领域处于全球领先地位，在个人化医疗、基因疗法和单株抗体方面投入了大量资金。将生物製剂开发和製造外包给合约开发组织（CDO）的趋势日益增长，这使得生物製药公司能够降低成本并专注于创新。此外，美国政府对研究资金和监管诱因的支持进一步强化了市场格局。随着对精准医疗的日益重视，美国生物製剂合约开发市场预计将继续保持强劲的成长轨迹。

生物製剂合约开发市场-竞争格局：

生物製剂合约开发市场的竞争格局特征是存在几家专注于先进技术、法规遵循和具有成本效益的解决方案的关键参与者。龙沙集团、药明康德和三星生物等公司凭藉其在生物药物开发领域的广泛服务（包括製程开发、製造和临床试验支援）引领市场。例如，龙沙集团 (Lonza Group) 提供最先进的设施和专业知识，用于大规模生物製剂生产，尤其是单株抗体生产。药明康德以其涵盖药物发现、开发和製造的一体化服务而闻名，并且专注于个人化医疗。三星生物製剂结合尖端的生物製造能力，着重营运效率和法规遵循。这些公司与製药公司和生技公司保持着密切的关係，将自己定位为生物开发领域的首选合作伙伴。他们扩大生产规模、确保品质控制和适应不断变化的监管标准的能力继续增强他们的竞争优势。

最新动态：

2023 年 2 月，Lonza 在美国建立了一个专注于开发临床试验早期药物的新实验室，扩大了其业务范围。

目录

第 1 章：生物製剂合约开发市场概览

  • 研究范围
  • 市场估计年限

第 2 章：执行摘要

  • 市场片段
    • 生物製剂合约开发市场片段（按服务类型）
    • 生物製剂合约开发市场片段（按生物製剂类型）
    • 生物製剂合约开发市场片段（按最终用户）
    • 生物製剂合约开发市场（按国家/地区）摘要
    • 生物製剂合约开发市场片段（按地区）
  • 竞争洞察

第 3 章：生物製剂合约开发关键市场趋势

  • 生物製剂合约开发市场驱动因素
    • 市场驱动因素的影响分析
  • 生物製剂合约开发市场限制
    • 市场限制的影响分析
  • 生物製剂合约开发市场机会
  • 生物製剂合约开发市场未来趋势

第 4 章：生物製剂合约开发产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景规划
  • 规范架构分析

第五章：生物製剂合约开发市场：地缘政治紧张局势升级的影响

  • 新冠肺炎疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第 6 章：生物製剂合约开发市场格局

  • 2024 年生物製剂合约开发市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第 7 章：生物製剂合约开发市场 - 按服务类型

  • 概述
    • 按服务类型分類的细分市场占有率分析
    • 合约研究
    • 合约製造
    • 合约测试

生物製剂合约开发市场 - 依生物製剂类型

  • 概述
    • 按生物製剂类型分類的细分市场份额分析
    • 单株抗体
    • 疫苗
    • 基因疗法
    • 重组蛋白

第 8 章：生物製剂合约开发市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 製药公司
    • 生技公司
    • 学术及研究机构

第 9 章：生物製剂合约开发市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美生物製剂合约开发主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测，按服务类型
    • 北美市场规模及预测（依生物製剂类型）
    • 北美市场规模及预测（按最终用户）
    • 美国
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲生物製剂合约开发主要製造商
    • 欧洲市场规模及预测（按国家）
    • 欧洲市场规模及预测（按服务类型）
    • 欧洲市场规模及预测（依生物製剂类型）
    • 欧洲市场规模及预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区生物製剂合约开发主要製造商
    • 亚太地区市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依服务类型）
    • 亚太地区生物製剂市场规模及预测
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲 (LATAM)
    • 概述
    • 拉丁美洲生物製剂合约开发主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按服务类型）
    • 拉丁美洲市场规模及预测（依生物製剂类型）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲 (MEA)
    • 概述
    • 中东和非洲生物製剂合约开发主要製造商
    • MEA 市场规模及预测（依国家/地区划分）
    • MEA 市场规模和预测（按服务类型）
    • MEA 市场规模及预测（依生物製剂类型）
    • MEA 市场规模及预测（依最终用户）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其他地区

第 10 章：主要供应商分析-生物製剂合约开发产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Lonza Group
    • WuXi AppTec
    • Samsung Biologics
    • Catalent
    • Boehringer Ingelheim
    • AbbVie
    • Fujifilm Diosynth Biotechnologies
    • CordenPharma
    • Samsung Biologics
    • Patheon (Thermo Fisher Scientific)
    • Merck KGaA
    • KBI Biopharma
    • Recipharm
    • Minaris Regenerative Medicine
    • Syngene International
    • Rentschler Biopharma
    • Almac Group
    • Emergent BioSolutions

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4643

REPORT HIGHLIGHT

Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.

The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) offer services ranging from early-stage research, process development, and clinical trials, to large-scale manufacturing. These partnerships help biopharma companies reduce costs, improve efficiency, and access specialized expertise. As the demand for biologics grows, driven by advancements in personalized medicine and rare diseases, the biologics contract development market continues to expand, with companies focusing on regulatory compliance, innovation, and cost-effective solutions.

Biologics Contract Development Market- Market Dynamics

Rising demand for personalized medicine driving biologics contract development growth.

The rising demand for personalized medicine is a significant driver for the biologics contract development market. Personalized medicine tailors' treatments to individual genetic profiles, improving efficacy and reducing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is projected to reach $3.5 trillion by 2025.

As biological therapies are central to personalized medicine, the need for specialized contract development services grows. The increasing prevalence of genetic disorders and cancer further fuels demand for biologics, with the NIH estimating that about 1 in 10 people globally are living with a rare disease, many requiring biological treatments. These factors have pushed biopharma companies to partner with contract development organizations to access the necessary expertise and scale production efficiently.

Biologics Contract Development Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.94% over the forecast period (2025-2032)

Based on Service Type segmentation, Contract Manufacturing was predicted to show maximum market share in the year 2024

Based on Biologics Type segmentation, Monoclonal Antibodies were the leading Biologics Type in 2024

Based on region, North America was the leading revenue generator in 2024

Biologics Contract Development Market- Segmentation Analysis:

The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.

The market is divided into three categories based on Service Type: Contract Research, Contract Manufacturing, and Contract Testing. The most dominant segment in the biologics contract development market is Contract Manufacturing. This segment has seen substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment needed to produce biologics efficiently while maintaining regulatory compliance. As biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and time-to-market. The need for scalable manufacturing solutions, particularly with the rise of personalized medicine and biological therapies for complex diseases, has solidified the importance of this segment.

The market is divided into four categories based on Biologics Type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. The most dominant segment in the biologics contract development market is Monoclonal Antibodies. This segment leads due to the growing demand for monoclonal antibodies (mAbs) in the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. With advancements in biotechnology, many new mAbs have been developed, contributing to their widespread use in personalized medicine. As a result, contract development organizations (CDOs) are increasingly focused on providing services for the development and manufacturing of mAbs, making this segment the most prominent in the biologics contract development market.

Biologics Contract Development Market- Geographical Insights

North America holds a significant share of the biologics contract development market, driven by the robust healthcare infrastructure, strong research capabilities, and the high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. North America is home to several leading biopharma companies, academic institutions, and contract development organizations, making it a key hub for biologics development. The U.S. has a high incidence of chronic diseases, including cancer and autoimmune disorders, which further accelerates the demand for biologic treatments. Additionally, the region's healthcare policies support innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing manufacturing and development services to specialized CDOs also adds to the market's growth. With advancements in genomics and biotechnology, North America is positioned to continue leading in biologics development and contract services.

The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The U.S. Food and Drug Administration (FDA) provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The country has a high prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which propels the demand for biological treatments. Furthermore, the U.S. is a global leader in biotechnology and pharmaceutical innovation, with significant investments in personalized medicine, gene therapies, and monoclonal antibodies. The increasing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) allows biopharma companies to reduce costs and focus on innovation. Moreover, the U.S. government's support for research funding and regulatory incentives further strengthens the market landscape. With a growing emphasis on precision medicine, the biologics contract development market in the U.S. is expected to continue its strong growth trajectory.

Biologics Contract Development Market- Competitive Landscape:

The competitive landscape of the biologics contract development market is marked by the presence of several key players focusing on advanced technologies, regulatory compliance, and cost-effective solutions. Companies like Lonza Group, WuXi AppTec, and Samsung Biologics lead the market with their extensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. Lonza Group, for example, offers state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and regulatory adherence. These companies maintain strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in the biologic development space. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to fuel their competitive advantage.

Recent Developments:

In February 2023, Lonza expanded its footprint in the U.S. with the establishment of a new laboratory focused on developing drugs in the early stages of clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza Group
  • WuXi AppTec
  • Samsung Biologics
  • Catalent
  • Boehringer Ingelheim
  • AbbVie
  • Fujifilm Diosynth Biotechnologies
  • CordenPharma
  • Samsung Biologics
  • Patheon (Thermo Fisher Scientific)
  • Merck KGaA
  • KBI Biopharma
  • Recipharm
  • Minaris Regenerative Medicine
  • Syngene International
  • Rentschler Biopharma
  • Almac Group
  • Emergent BioSolutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research
  • Contract Manufacturing
  • Contract Testing

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Vaccines
  • Gene Therapies
  • Recombinant Proteins

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics Contract Development Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics Contract Development Market Snippet by Service Type
    • 2.1.2. Biologics Contract Development Market Snippet by Biologics Type
    • 2.1.3. Biologics Contract Development Market Snippet by End-User
    • 2.1.4. Biologics Contract Development Market Snippet by Country
    • 2.1.5. Biologics Contract Development Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics Contract Development Key Market Trends

  • 3.1. Biologics Contract Development Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics Contract Development Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics Contract Development Market Opportunities
  • 3.4. Biologics Contract Development Market Future Trends

4. Biologics Contract Development Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics Contract Development Market Landscape

  • 6.1. Biologics Contract Development Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics Contract Development Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Contract Research
    • 7.1.3. Contract Manufacturing
    • 7.1.4. Contract Testing

Biologics Contract Development Market - By Biologics Type

  • 7.2. Overview
    • 7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Vaccines
    • 7.2.4. Gene Therapies
    • 7.2.5. Recombinant Proteins

8. Biologics Contract Development Market - By End-User

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 8.1.2. Pharmaceutical Companies
    • 8.1.3. Biotechnology Companies
    • 8.1.4. Academic & Research Institutions

9. Biologics Contract Development Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Biologics Contract Development Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.7. The U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Biologics Contract Development Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.8. UK
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.10. Italy
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.11. Spain
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.12. The Netherlands
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.13. Sweden
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.14. Russia
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.15. Poland
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.16. Rest of Europe
      • 9.3.16.1. Overview
      • 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.8. India
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.11. Australia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.13. Thailand
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.14. Philippines
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.15. Rest of APAC
      • 9.4.15.1. Overview
      • 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Biologics Contract Development Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.10. Colombia
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.11. Rest of LATAM
      • 9.5.11.1. Overview
      • 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.8. UAE
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.9. Israel
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.10. Turkey
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.11. Algeria
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.12. Egypt
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.13. Rest of MEA
      • 9.6.13.1. Overview
      • 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biologics Contract Development Industry

  • 10.1. Competitive Dashboard
    • 10.1.1. Competitive Benchmarking
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Lonza Group
    • 10.2.2. WuXi AppTec
    • 10.2.3. Samsung Biologics
    • 10.2.4. Catalent
    • 10.2.5. Boehringer Ingelheim
    • 10.2.6. AbbVie
    • 10.2.7. Fujifilm Diosynth Biotechnologies
    • 10.2.8. CordenPharma
    • 10.2.9. Samsung Biologics
    • 10.2.10. Patheon (Thermo Fisher Scientific)
    • 10.2.11. Merck KGaA
    • 10.2.12. KBI Biopharma
    • 10.2.13. Recipharm
    • 10.2.14. Minaris Regenerative Medicine
    • 10.2.15. Syngene International
    • 10.2.16. Rentschler Biopharma
    • 10.2.17. Almac Group
    • 10.2.18. Emergent BioSolutions

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us